FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334803870> ?p ?o ?g. }

• W2334803870 endingPage "280" @default.
• W2334803870 startingPage "274" @default.
• W2334803870 abstract "Result of clinical trial for registration purpose is often difficult to generalize because of its limited population in number and inclusion criteria. To understand the efficacy of sorafenib under daily medical practice, we retrospectively investigated therapeutic outcomes of 175 Japanese patients with advanced renal cell carcinoma treated with sorafenib at 15 centers. The objective response rate and disease control rate were 15.4 and 77.1%, respectively, being similar to those in the Phase II study in Japanese patients (19.4 and 73.6 months). Any tumor shrinkage was observed with 53% of patients, while tumor control without growth was in 61%. Lung lesions were more sensitive to sorafenib than other lesions, in terms of any tumor shrinkage (54%) and the extent of maximal shrinkage, while tumor control was better in lymph node metastases (77%) than in lung (69%). Liver was worse in any tumor shrinkage (35%), tumor control (55%) and the extent of tumor growth. Slightly, shorter median overall survival of 21.1 months compared with Phase II clinical trial (25.3 months) is likely to be attributable to different patient population, because median overall survival was improved to 26.4 months when the population was matched to that in Phase II trial. Univariate and multivariate analyses identified prognostic factors for worse overall survival, including intermediate and poor Memorial Sloan-Kettering Cancer Center risk, Eastern Cooperative Oncology Group performance status ≥1, the presence of non-clear cell component and the presence of liver metastasis. In conclusion, the present study confirmed the efficacy of sorafenib in the real-world setting on advanced renal cell carcinoma." @default.
• W2334803870 created "2016-06-24" @default.
• W2334803870 creator A5004714456 @default.
• W2334803870 creator A5018910129 @default.
• W2334803870 creator A5022966046 @default.
• W2334803870 creator A5033431792 @default.
• W2334803870 creator A5033566028 @default.
• W2334803870 creator A5039844040 @default.
• W2334803870 creator A5047246036 @default.
• W2334803870 creator A5064341902 @default.
• W2334803870 creator A5064917014 @default.
• W2334803870 creator A5068644980 @default.
• W2334803870 creator A5068707626 @default.
• W2334803870 creator A5070428340 @default.
• W2334803870 creator A5082066515 @default.
• W2334803870 creator A5086644570 @default.
• W2334803870 creator A5089503656 @default.
• W2334803870 date "2014-11-23" @default.
• W2334803870 modified "2023-10-03" @default.
• W2334803870 title "Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib" @default.
• W2334803870 cites W1547252551 @default.
• W2334803870 cites W1914288745 @default.
• W2334803870 cites W1999966467 @default.
• W2334803870 cites W2012980021 @default.
• W2334803870 cites W2022169059 @default.
• W2334803870 cites W2023952988 @default.
• W2334803870 cites W2032993790 @default.
• W2334803870 cites W2037837794 @default.
• W2334803870 cites W2058736678 @default.
• W2334803870 cites W2138129102 @default.
• W2334803870 cites W2138822094 @default.
• W2334803870 cites W2145051877 @default.
• W2334803870 cites W2147663823 @default.
• W2334803870 cites W2155196945 @default.
• W2334803870 cites W2157262448 @default.
• W2334803870 cites W2160724351 @default.
• W2334803870 cites W2162225483 @default.
• W2334803870 doi "https://doi.org/10.1093/jjco/hyu200" @default.
• W2334803870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25420693" @default.
• W2334803870 hasPublicationYear "2014" @default.
• W2334803870 type Work @default.
• W2334803870 sameAs 2334803870 @default.
• W2334803870 citedByCount "5" @default.
• W2334803870 countsByYear W23348038702015 @default.
• W2334803870 countsByYear W23348038702016 @default.
• W2334803870 countsByYear W23348038702017 @default.
• W2334803870 crossrefType "journal-article" @default.
• W2334803870 hasAuthorship W2334803870A5004714456 @default.
• W2334803870 hasAuthorship W2334803870A5018910129 @default.
• W2334803870 hasAuthorship W2334803870A5022966046 @default.
• W2334803870 hasAuthorship W2334803870A5033431792 @default.
• W2334803870 hasAuthorship W2334803870A5033566028 @default.
• W2334803870 hasAuthorship W2334803870A5039844040 @default.
• W2334803870 hasAuthorship W2334803870A5047246036 @default.
• W2334803870 hasAuthorship W2334803870A5064341902 @default.
• W2334803870 hasAuthorship W2334803870A5064917014 @default.
• W2334803870 hasAuthorship W2334803870A5068644980 @default.
• W2334803870 hasAuthorship W2334803870A5068707626 @default.
• W2334803870 hasAuthorship W2334803870A5070428340 @default.
• W2334803870 hasAuthorship W2334803870A5082066515 @default.
• W2334803870 hasAuthorship W2334803870A5086644570 @default.
• W2334803870 hasAuthorship W2334803870A5089503656 @default.
• W2334803870 hasBestOaLocation W23348038701 @default.
• W2334803870 hasConcept C126322002 @default.
• W2334803870 hasConcept C143998085 @default.
• W2334803870 hasConcept C2776256026 @default.
• W2334803870 hasConcept C2777472916 @default.
• W2334803870 hasConcept C2777546739 @default.
• W2334803870 hasConcept C2778019345 @default.
• W2334803870 hasConcept C2778695046 @default.
• W2334803870 hasConcept C2908647359 @default.
• W2334803870 hasConcept C535046627 @default.
• W2334803870 hasConcept C71924100 @default.
• W2334803870 hasConcept C99454951 @default.
• W2334803870 hasConceptScore W2334803870C126322002 @default.
• W2334803870 hasConceptScore W2334803870C143998085 @default.
• W2334803870 hasConceptScore W2334803870C2776256026 @default.
• W2334803870 hasConceptScore W2334803870C2777472916 @default.
• W2334803870 hasConceptScore W2334803870C2777546739 @default.
• W2334803870 hasConceptScore W2334803870C2778019345 @default.
• W2334803870 hasConceptScore W2334803870C2778695046 @default.
• W2334803870 hasConceptScore W2334803870C2908647359 @default.
• W2334803870 hasConceptScore W2334803870C535046627 @default.
• W2334803870 hasConceptScore W2334803870C71924100 @default.
• W2334803870 hasConceptScore W2334803870C99454951 @default.
• W2334803870 hasIssue "3" @default.
• W2334803870 hasLocation W23348038701 @default.
• W2334803870 hasLocation W23348038702 @default.
• W2334803870 hasOpenAccess W2334803870 @default.
• W2334803870 hasPrimaryLocation W23348038701 @default.
• W2334803870 hasRelatedWork W2010915333 @default.
• W2334803870 hasRelatedWork W2020852956 @default.
• W2334803870 hasRelatedWork W2154171266 @default.
• W2334803870 hasRelatedWork W2290145882 @default.
• W2334803870 hasRelatedWork W2333326682 @default.
• W2334803870 hasRelatedWork W2517171178 @default.
• W2334803870 hasRelatedWork W2590369810 @default.
• W2334803870 hasRelatedWork W2901359921 @default.

• next